22.04.24 | Vollzeit | Mainz | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | München | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen22.04.24 | Vollzeit | Wiesbaden | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | Wiesbaden | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | Mannheim | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | Mainz | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | Planegg | CatalYm GmbHCatalYm GmbH is a well-funded, clinical-stage biotechnology company focused on revolutionizing cancer treatment through the development of Visugromab, an innovative immunotherapy designed for patients with advanced solid tumors. Visugromab targets the immunosuppressive cytokine GDF-15, which
Später ansehen22.04.24 | Vollzeit | Mainz | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehen22.04.24 | Vollzeit | Mainz | BioNTech SEScientific and ethical standards - writing medical history. We aim to reduce the suffering of people with life-changing therapies by harnessing the potential of the immune system to develop novel therapies against cancer and infectious diseases. While doing so, we are guided by our three company values
Später ansehenVerpassen Sie nie wieder einen passenden Job!
Alle Jobs für Immune System Development in Deutschland kostenlos abonnieren.